| Literature DB >> 24151548 |
Denise C Cooper1, Ranak B Trivedi, Karin M Nelson, Gayle E Reiber, Alan B Zonderman, Michele K Evans, Shari R Waldstein.
Abstract
Young to middle-aged women usually have notably lower rates of cardiovascular disease (CVD) than their male counterparts, but African American women lack this advantage. Their elevated CVD may be influenced by sex differences in associations between depressed mood and CVD risk factors. This cross-sectional study examined whether relations between scores on the Center for Epidemiologic Studies-Depression (CES-D) scale and a spectrum of CVD risk factors varied by sex among African Americans (n = 1076; ages 30-64) from the Healthy Aging in Neighborhoods of Diversity across the Life Span (HANDLS) study. Sex-stratified multiple regressions and logistic regressions were conducted. Among women, CES-D scores correlated positively with systolic blood pressure and waist-to-hip ratio (P's < .05), but inversely with high-density lipoprotein cholesterol (HDL-C) (P < .01). Women had twice the odds for metabolic syndrome if CES-D scores ≥16 and had a ≥14% increase in odds of hypertension, abdominal obesity, and low HDL-C with each 5-unit increase in CES-D scores. Among men, CES-D scores correlated positively with high-sensitivity C-reactive protein (P < .05), and odds of hypertension increased by 21% with each 5-unit increase in CES-D scores. Depressive symptoms may promote premature CVD risk in African Americans, at least in part, via CVD risk factors and prevalent metabolic syndrome, particularly in African American women.Entities:
Year: 2013 PMID: 24151548 PMCID: PMC3787626 DOI: 10.1155/2013/979185
Source DB: PubMed Journal: Cardiovasc Psychiatry Neurol ISSN: 2090-0171
Sample characteristics and sex differences.
| Variable (raw scores) | Total ( | Women ( | Men ( |
|---|---|---|---|
| Sociodemographic and lifestyle covariates | |||
| Age (yrs) | 48.2 (9.1) | 48.3 (9.3) | 48.0 (8.9) |
| Poverty (per Federal guidelines) % | 42.5 | 43.8 | 41.1 |
| Smoking history (lifetime ≥100 cigarettes)%*** | 71.4 | 65.0 | 78.8 |
| Alcohol (consumed in past week)%*** | 41.4 | 34.4 | 49.5 |
| Drug History (lifetime coke/opiate/cannabis ≥5x)%*** | 58.7 | 45.7 | 73.7 |
| Biomedical covariates | |||
| BMI (kg/m2)*** | 30.1 (7.8) | 32.3 (8.6) | 27.4 (5.8) |
| Medical History of CVD %*** | 22.9 | 27.6 | 17.3 |
| Medical history of hypertension*** | 44.9 | 51.2 | 37.7 |
| Medical history of diabetes % | 17.4 | 17.9 | 16.7 |
| Antihypertensive medication use %*** | 35.6 | 41.7 | 28.5 |
| Antidiabetes medication use % | 13.4 | 13.7 | 13.0 |
| Cholesterol-reduction medication use | 12.6 | 14.1 | 11.0 |
| Antidepressant medication use %** | 9.4 | 12.0 | 6.5 |
| Hormone replacement therapy use % | 0.7 | 1.2 | n/a |
| Menopause % | 23.3 | 43.4 | n/a |
| Predictor and outcome variables | |||
| CES-D* | 11.3 (7.8) | 11.8 (8.5) | 10.7 (6.8) |
| CESD ≥ 16** | 25.8 | 29.5 | 21.6 |
| Hypertensiona %*** | 52.6 | 57.8 | 46.6 |
| Mean SBP (mmHg) | 122.2 (17.4) | 122.8 (18.5) | 121.4 (16.1) |
| Mean DBP (mmHg)* | 73.5 (11.2) | 72.7 (11.0) | 74.5 (11.4) |
| WHR obesity: ≥0.90 ♂ and ≥0.85 ♀ %** | 67.2 | 71.4 | 62.3 |
| Mean WHR*** | 0.92 (0.01) | 0.90 (0.1) | 0.94 (0.1) |
| Mean waist circumference (cm)*** | 99.0 (17.5) | 102.1 (18.3) | 95.4 (15.8) |
| Hypercholesterolemiab % | 20.2 | 22.7 | 17.6 |
| Mean CHOL (mg/dL) | 183.7 (44.9) | 184.6 (38.8) | 182.9 (50.7) |
| Low HDL-C: <40 ♂ and <50 ♀ (mg/dL) %*** | 33.7 | 43.1 | 23.6 |
| Mean HDL-C (mg/dL) | 55.3 (18.4) | 55.9 (16.0) | 54.6 (20.7) |
| High LDL-C: >160 mg/dL % | 7.4 | 8.2 | 7.2 |
| Mean LDL-C (mg/dL) | 107.7 (37.1) | 108.4 (34.8) | 106.9 (39.4) |
| High TG: >200 mg/dL % | 6.1 | 4.3 | 8.0 |
| Mean TG (mg/dL) | 105.7 (85.4) | 101.3 (50.6) | 110.3 (111.1) |
| Diabetesc % | 18.7 | 20.8 | 16.3 |
| Mean GLU (mg/dL) | 106.5 (46.3) | 110.0 (53.1) | 102.8 (37.4) |
| High hsCRP: ≥3 mg/L %*** | 38.9 | 46.9 | 30.4 |
| Mean hsCRP (mg/L) | 5.9 (14.6) | 6.7 (12.5) | 5.0 (16.5) |
aHypertension: SBP ≥ 140 or DBP ≥ 90 or prior diagnosis or use of antihypertensive medication.
bHypercholesterolemia: fasting CHOL > 240 mg/dL or use of cholesterol-reduction medication. cDiabetes: fasting GLU: ≥126 mg/dL or prior diagnosis or use of antidiabetes medication.
Sex differences: ***P < .001; **P < .01; *P < .05.
Regression coefficients of associations between CES-D scores and CVD risk factors (continuous scores) by sex.
| Outcome variable | Women | Men | ||||||
|---|---|---|---|---|---|---|---|---|
| CES-D scores (0 to 60 points) | CES-D scores (0 to 60 points) | |||||||
|
|
|
|
|
|
|
|
| |
| SBP (mmHg) | 573 | .08 | .001 (.00) | .042* | 494 | .06 | .000 (.00) | .183 |
| DBP (mmHg) | 573 | .08 | .001 (.00) | .077‡ | 494 | −.01 | .000 (.00) | .861 |
| WHR | 582 | .10 | .001 (.00) | .016* | 483 | −.04 | .000 (.00) | .346 |
| CHOL (mg/dL) | 254 | −.10 | −.469 (.29) | .111 | 239 | .05 | .378 (.53) | .480 |
| HDL-C (mg/dL) | 254 | −.18 | −.355 (.12) | .003** | 238 | .07 | .216 (.19) | .257 |
| LDL-C (mg/dL) | 254 | −.03 | −.137 (.26) | .598 | 237 | .07 | .391 (.41) | .338 |
| TG (mg/dL) | 254 | .02 | .117 (.40) | .767 | 239 | −.05 | −.771 (1.2) | .504 |
| GLU (mg/dL) | 308 | .01 | .078 (.28) | .782 | 284 | −.08 | −.561 (.35) | .114 |
| hsCRP (mg/L) | 254 | .00 | .001 (.10) | .988 | 238 | .17 | .421 (.17) | .011* |
Significance values for the CES-D in multiple regression models: **P < .01; *P < .05; ‡ P = .07.
Data shown are for multiple regressions after adjustments for age, poverty status, BMI; histories of CVD, hypertension, and/or diabetes; medication use (i.e., antihypertensive, antidiabetes, cholesterol reduction, antidepressants, and hormone replacement therapy); menopausal status; lifetime histories of smoking and drug use; and alcohol use in past week. (Exceptions: covariates BMI, history of hypertension, and history of diabetes were omitted from the models for WHR, SBP/DBP, and fasting glucose, resp. Menopause status and hormone replacement therapy were omitted from models for men.)
Adjusted odds of associations between the CES-D (continuous scores) and CVD risk factors (clinical cut-offs) by sex.
| Outcome variable | Women | Men | ||||||
|---|---|---|---|---|---|---|---|---|
| CES-D scores (0 to 60 points) | CES-D scores (0 to 60 points) | |||||||
|
| Odds ratio | 95% confidence interval |
|
| Odds ratio | 95% confidence interval |
| |
| Hypertension | ||||||||
| High SBP ≥140 or DBP ≥90 mmHg (or prior hypertension diagnosis/treatment) | 573 | 1.16 | 1.02, 1.31 | .022* | 494 | 1.21 | 1.03, 1.43 | .022* |
| Abdominal obesity | ||||||||
| High WHR ≥0.9 ♂ and ≥0.85 ♀ | 562 | 1.14a | 1.00, 1.29 | .048* | 483 | 0.99 | 0.85, 1.15 | .869 |
| Dyslipidemia | ||||||||
| Hypercholesterolemia: | 268 | 0.98 | 0.79, 1.22 | .876 | 247 | 0.94 | 0.71, 1.24 | .652 |
| Low HDL-C <40 ♂ and <50 ♀ mg/dL | 254 | 1.22 | 1.03, 1.45 | .019* | 238 | 0.91 | 0.70, 1.16 | .438 |
| High LDL-C: >160 mg/dL | 254 | 1.09 | 0.81, 1.46 | .584 | 237 | 1.45 | 0.97, 2.16 | .073‡ |
| High TG >200 mg/dL | 254 | 1.17 | 0.81, 1.70 | .407 | 239 | 1.09 | 0.77, 1.55 | .631 |
| Diabetes | ||||||||
| Fasting GLU ≥126 mg/dL or prior diabetes diagnosis/treatment | 321 | 0.96 | 0.78, 1.18 | .677 | 292 | 1.05 | 0.79, 1.40 | .751 |
| High inflammation | ||||||||
| High hsCRP ≥3 mg/L | 254 | 0.98 | 0.81, 1.18 | .845 | 238 | 1.16 | 0.89, 1.50 | .269 |
Odds ratios for outcome variables are based on a 5-unit change in CES-D score.
Significance for the CES-D in models: *P < .05; ‡ P = .07. aThe confidence interval includes 1 due to rounding.
Data shown are for logistic regressions after adjustments for age, poverty status, and BMI; histories of CVD, hypertension, and/or diabetes; medication use (antidiabetes, antihypertensive, cholesterol reduction, anti depressants, and hormone replacement therapy); menopausal status; lifetime histories of smoking and drug use; and alcohol use in past week. (Exceptions: covariates BMI, history of hypertension/antihypertensive medications, history of diabetes/antidiabetes medication, and cholesterol-reduction medication were omitted from the models for WHR, hypertension, diabetes, and hypercholesterolemia, resp. Menopause status and hormone replacement therapy were omitted from models for men.)
Adjusted odds of associations between the CES-D 16 and metabolic syndrome by sex.
| Outcome variable | Women | Men | ||||||
|---|---|---|---|---|---|---|---|---|
| CES-D scores ≥16 | CES-D scores ≥16 | |||||||
|
| Odds ratio | 95% confidence interval |
|
| Odds ratio | 95% confidence interval |
| |
| Metabolic syndrome | 251 | 2.64 | 1.19, 5.83 | .017 | 233 | 1.35 | 0.43, 4.24 | .603 |
Odds adjusted for age, poverty status, and BMI; histories of CVD, hypertension, and/or diabetes; medication use (antidiabetes, antihypertensive, cholesterol reduction, and antidepressant); hormone replacement therapy and menopausal status (in women); lifetime histories of smoking and drug use; and alcohol use in past week.